Everolimus and Phenytoin Capsules
Determining the interaction of Everolimus and Phenytoin Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Phenytoin may reduce the blood levels of everolimus, which may make it less effective in treating your condition. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects of everolimus. In a study of healthy volunteers, multiple doses of the potent inducer rifampin increased the oral clearance of everolimus by threefold, representing mean decreases in peak blood concentration (Cmax) and systemic exposure (AUC) of 58% and 63%, respectively.
MANAGEMENT: Concomitant use of everolimus with potent CYP450 3A4 and/or P-gp inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered. Some manufacturers recommend that, if concomitant use is unavoidable, the daily everolimus dose should be doubled to achieve the recommended therapeutic range for the condition being treated. Please refer to the manufacturer's labeling for specific dosing information. If the potent CYP450 3A4 and/or P-gp inducer is discontinued, the everolimus dosage should be returned to the dosage used before the potent inducer was commenced after a washout period of approximately 3 to 5 days. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase, and 2 weeks after discontinuation of the potent inducers.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Zortress (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: everolimus
Brand name: Zortress, Afinitor, Afinitor Disperz
Synonyms: n.a.
Generic Name: phenytoin
Brand name: Dilantin, Phenytek, Dilantin Infatabs, Phenytoin Sodium, Prompt
Synonyms: Phenytoin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Everolimus-Phenytoin Chewable Tablets
- Everolimus-Phenytoin Extended-Release Capsules
- Everolimus-Phenytoin Infatabs
- Everolimus-Phenytoin injection
- Everolimus-Phenytoin Intravenous
- Everolimus-Phenytoin Oral Suspension
- Phenytoin Capsules-Everolimus Tablets (Afinitor)
- Phenytoin Capsules-Everolimus Tablets (Zortress)
- Phenytoin Capsules-Everolimus Tablets For Oral Suspension
- Phenytoin Capsules-Evista
- Phenytoin Capsules-Evoclin
- Phenytoin Capsules-Evoclin Topical